AimwellBio Enhances Behavioral Engagement Platform with Trustr IP Acquisition and Dr. Chris A. Jones Joining Advisory Board

AimwellBio (OTC:AIMN) has published a confidential investor briefing detailing its recent acquisition of the Trustr behavioral engagement intellectual property portfolio, which the company values at $10 million. The portfolio comprises a U.S. patent family covering systems that measure real-world behavior against personalized performance indicators and deliver precisely timed reward and loss-aversion messages to promote sustained behavioral change.

The technology underlying Trustr has a documented institutional lineage. It was originally licensed through the University of Vermont Office of Technology and Commercialization and underwent evaluation by the Cornell Consulting Group as early as 2015. The platform also received a Gold Ribbon award at the Academy of Managed Care Pharmacy (AMCP) conference in 2020 and was piloted in a Sanofi program targeting moderate-to-severe asthma patients.

AimwellBio intends to leverage this behavioral engagement technology as a foundational layer supporting applications such as medication adherence, remote patient monitoring, clinical trial retention, and patient-reported outcomes. The investor briefing offers a comprehensive review of the patent filings, platform architecture, development history, and the key individuals and institutions involved.

The briefing also identifies outstanding diligence items that remain under review or require confirmation, reflecting AimwellBio’s commitment to transparency and thorough due diligence. John Morgan, Principal of AimwellBio, emphasized this approach, stating, "Anyone can tell investors they have intellectual property. We would rather provide the record—the filings, the institutions, the people, the history, and the questions we are still working to close out. Investors should be able to see what is tangible and understand exactly what we are building from."

In a significant development, Dr. Chris A. Jones, D.Phil. (Oxford), the inventor of the Trustr portfolio and a behavioral economist whose doctoral work earned the Bertarelli Prize, has joined AimwellBio’s Board of Advisors. Dr. Jones will lead efforts to expand the platform by introducing and evaluating additional intellectual property, technologies, assets, and experienced operators.

Dr. Jones remarked, "Trustr was built to influence what patients actually do between visits, which is often where healthcare outcomes are won or lost. AimwellBio provides an opportunity to expand that technology into a broader platform. Trustr is the beginning of what I intend to bring to the AimwellBio ecosystem in terms of intellectual property, assets, and people."

The investor briefing is available to current and prospective investors upon request through AimwellBio Investor Relations. It provides detailed visibility into the patents, platform architecture, institutional affiliations, and the company’s ongoing diligence efforts.

AimwellBio’s acquisition and transparent disclosure of the Trustr portfolio underscore its strategic focus on integrating behavioral engagement technologies to enhance patient outcomes and real-world evidence generation. The addition of Dr. Jones to the advisory board further positions the company to accelerate innovation and intellectual property development within its platform ecosystem.